Michael McCall
Direttore/Membro del Consiglio presso Select Therapeutics, Inc.
Profilo
Michael McCall has worked as a Director at Select Therapeutics, Inc. since 2001 and at Cytomatrix since 1999.
Posizioni attive di Michael McCall
| Società | Posizione | Inizio |
|---|---|---|
Select Therapeutics, Inc.
 Select Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Select Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is focused on the development of cell based therapeutics production. The company was founded by Clifford A. Lingwood in January 1997 and is headquartered in Brookline, MA. | Direttore/Membro del Consiglio | 22/02/2010 |
Cytomatrix
 Cytomatrix Miscellaneous Commercial ServicesCommercial Services Part of Cordlife Group Ltd., Cytomatrix is a company that researches, develops, and commercializes novel cell growth systems for hematopoietic (blood) stem cells. The company is based in Woburn, MA. The company was founded by Mark Jerome Pykett. Cytomatrix was acquired by Cordlife Group Ltd. on April 30, 2003 for $11 million. | Direttore/Membro del Consiglio | 22/02/2010 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Select Therapeutics, Inc.
Select Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Select Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is focused on the development of cell based therapeutics production. The company was founded by Clifford A. Lingwood in January 1997 and is headquartered in Brookline, MA. | Health Technology |
Cytomatrix
Cytomatrix Miscellaneous Commercial ServicesCommercial Services Part of Cordlife Group Ltd., Cytomatrix is a company that researches, develops, and commercializes novel cell growth systems for hematopoietic (blood) stem cells. The company is based in Woburn, MA. The company was founded by Mark Jerome Pykett. Cytomatrix was acquired by Cordlife Group Ltd. on April 30, 2003 for $11 million. | Commercial Services |
- Borsa valori
- Insiders
- Michael McCall
